SAN DIEGO, CA / ACCESSWIRE / December 8, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Mesoblast Limited (OTC PINK:MEOBF) shares.
Investors, who purchased shares of Mesoblast Limited (OTC PINK:MEOBF), have certain options and should contact the Shareholders Foundation at [email protected] or call +1 (858) 779 -1554.
The plaintiff alleges that the defendants failed to disclose to investors, that comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory aGVHD due to design differences between the four studies, that, as a result, the FDA was reasonably likely to require further clinical studies, that, as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased Mesoblast Limited (OTC PINK:MEOBF) shares should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
SOURCE: Shareholders Foundation, Inc.